Veradermics initiated with an Overweight at Cantor Fitzgerald

As previously reported, Cantor Fitzgerald analyst Prakhar Agrawal initiated coverage of Veradermics (MANE) with an Overweight rating and no price target Veradermics is a late clinical-stage biotech focused on dermatology and aesthetic conditions, the analyst tells investors in a research note. The firm says the company has leveraged the “validated biology” of minoxidil for pattern hair loss and optimized its pharmacokinetics to improve efficacy and reduce safety risks. Cantor sees a large total addressable market for minoxidil says there has recently been an inflection in demand for pattern hair loss products.